iRhythm receives FDA warning letter on California plant inspection

• The US FDA has issued a warning letter to iRhythm Technologies (NASDAQ:IRTC) related to an inspection of a Cypress, Calif., facility.
• The agency is alleging non-conformities to medical device regulations related to iRhythm's (IRTC) Zio AT System and medical device quality system requirements.
• The company said it will work with the FDA to address the concerns.

More on iRhythm Technologies

• iRhythm: Revolutionizing Arrhythmia Detection With AI And Machine Learning

• iRhythm: AI Products May Be Better Than Cardiologists And Stock Looks Cheap